ARID3A and esophageal squamous cell carcinoma: ARID3A activities of inhibiting cell differentiation, promoting cell proliferation, and increasing cell survival potential have been implicated in some developmental pathways, and reported as oncogenic in different other cancer types, with the binding site “a” of Figure 4 validated in esophageal squamous cell carcinoma [50,51,52,53,54].